Abstract
Background/purpose: Personalized dosing of monoclonal antibodies (mAbs) based on body weight and surface area may result in leftovers that need to be discarded due to the absence of stability data. After manufacturing, these mAbs undergo extensive quality control with a panel of methods. With some of these similar methods, these mAbs could be tested to see if stability is maintained after the opening of the pharmaceutical product vial and dilution for administration in a daily clinical setting. Prolonged in-use stability may reduce unnecessary waste and minimize the financial loss of these expensive drugs. Methods: Previously, based on extensive literature research, a complementary panel of methods was selected including visual inspection colour, apparency and, clarity (CAC), size exclusion chromatography (SEC), enzyme-linked immunosorbent assay (ELISA), dynamic light scattering (DLS), thermal denaturation (Tm), and aggregation (Tagg) determination, pH and dye ingress method. We evaluated, developed, and validated these methods with respect to the accuracy, precision, reproducibility, stability-indicating capability, carry-over, limit of quantification (LOQ) and limit of detection (LOD) for nivolumab and pembrolizumab as prototype anticancer mAbs. Results: Analytical results show that stability can be determined from a physiochemical, biological, and microbiological point of view with the selected methods. Forced degradation studies showed that even small instabilities can be detected using the panel of methods together, therefore the stability-indicating capability has been established. CAC shows mainly aggregation and discolouration. SEC shows aggregation and fragmentation/degradation, DLS gives information about turbidity and soluble aggregates, Tm and Tagg give information changes intra- and inter conformational changes, respectively, in the mAb molecule. ELISA shows potential loss in bioactivity and the pH of the sample is essential to the chemical composition of the mAb molecules in the solution. Conclusion: A panel of analytical methods was selected, enabling in-use stability determination of anticancer mAbs. This panel will be used in future studies to determine the prolonged use of leftover anticancer mAb products and infusion solutions, starting with nivolumab and pembrolizumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.